The pharmaceutical stock can still deliver.
Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...
Eli Lilly’s stock has recently seen its consensus analyst price target rise from $1,003 to $1,024. This change reflects ...
Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing ...
Pfizer's weight management pipeline just got a boost.
Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally ...
The possibility of adding a new Big Tech customer helped lift an American chipmaker's stock on Friday, Nov. 28, 2025, while a ...
Shares of Eli Lilly and Company (LLY), the world’s largest pharmaceutical producer, have experienced a remarkable rally this month.
Eli Lilly stock was rising Thursday after the drugmaker beat estimates for third-quarter results but dramatically slashed its full-year earnings outlook on the back of a deal spree. Lilly (ticker: LLY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback